Peijia Medical-B (09996): The State Drug Administration accepted the registration application for TaurioTM transcatheter aortic valve system

^{Zhitong Finance App News, Peijia Medical-B (09996) issued an announcement. Recently, the company received an acceptance notice from the China National Drug Administration confirming acceptance of the registration application for the TaurTrio TM transcatheter aortic valve (TAV) system.}

The TauriO ^TM TAV system is developed and manufactured by the company based on an exclusive license obtained from JenaValve Technology, Inc. and is specifically designed to treat patients with primary severe aortic valve reflux through the femoral artery access. The system was accepted by the State Drug Administration's special approval procedure for innovative medical devices in June 2023, and priority evaluation and approval will be given during the registration application process.